Shares of InVivo Therapeutics stock opened at $0.34 on Monday. InVivo Therapeutics has a 52-week low of $0.26 and a 52-week high of $0.93. The company has a 50 day moving average of $0.33 and a 200 day moving average of $0.47.
Several large investors have recently modified their holdings of the company. Virtu Financial LLC purchased a new stake in shares of InVivo Therapeutics during the 4th quarter worth approximately $58,000. Morgan Stanley lifted its position in shares of InVivo Therapeutics by 1,525.9% during the 2nd quarter. Morgan Stanley now owns 50,697 shares of the biotechnology company’s stock worth $38,000 after buying an additional 47,579 shares during the last quarter. Two Sigma Securities LLC purchased a new stake in shares of InVivo Therapeutics during the 3rd quarter worth approximately $31,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of InVivo Therapeutics during the 2nd quarter worth approximately $30,000. Institutional investors and hedge funds own 5.49% of the company’s stock.
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI.
- Get a free copy of the StockNews.com research report on InVivo Therapeutics (NVIV)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Ross Stores On The Verge Of Major Rally
- Insiders Are Selling Palo Alto Networks
Receive News & Ratings for InVivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.